$0.15
(Market cap
$848 Mln
Recently Viewed
Clear AllMarket cap
$848 Mln
Revenue (TTM)
$107 Mln
P/E Ratio
8
P/B Ratio
2.8
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$0 Mln
ROE
0.4 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
4.2
Debt to Equity
0.3
Book Value
$5.6
EPS
$2
Face value
--
Shares outstanding
51,492,924
CFO
$-1,667.37 Mln
EBITDA
$-1,738.41 Mln
Net Profit
$-1,972.77 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Theravance Biopharma (TBPH)
| -12.0 | 11.6 | -18.7 | 74.2 | 12.5 | -4.9 | -3.8 |
|
BSE Sensex
| -9.5 | 5.5 | -6.0 | -4.3 | 8.7 | 9.9 | 11.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Theravance Biopharma (TBPH)
| 98.8 | 0.2 | 1.5 | -37.8 | -31.4 | 1.2 |
|
S&P Small-Cap 600
| 4.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Theravance Biopharma (TBPH)
|
16.5 | 847.6 | 107.5 | 105.9 | -1.8 | 44.8 | 8 | 2.8 |
| 0.9 | 7.3 | 0.0 | -1.4 | -- | -6.2 | -- | 0.3 |
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary... disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California. Read more
Chairman & CEO
Mr. Rick E. Winningham M.B.A.
Chairman & CEO
Mr. Rick E. Winningham M.B.A.
Headquarters
South San Francisco, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Theravance Biopharma Inc (TBPH) is $16.46 (NASDAQ) as of 24-Apr-2026 16:00 EDT. Theravance Biopharma Inc (TBPH) has given a return of 12.5% in the last 3 years.
The P/E ratio of Theravance Biopharma Inc (TBPH) is 7.99 times as on 24-Apr-2026.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
9.37
|
3.35
|
|
2024
|
-8.22
|
2.64
|
|
2023
|
-10.06
|
2.61
|
|
2022
|
0.87
|
1.71
|
|
2021
|
-4.10
|
-2.41
|
The 52-week high and low of Theravance Biopharma Inc (TBPH) are Rs 21.03 and Rs 8.33 as of 26-Apr-2026.
Theravance Biopharma Inc (TBPH) has a market capitalisation of $ 848 Mln as on 24-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Theravance Biopharma Inc (TBPH), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.